COGENT BIOSCIENCES INC reports a Return on Equity (ROE) of -58.30%.

What is COGT's dividend yield?

COGENT BIOSCIENCES INC offers a dividend yield of 0.00%.

What is COGT's Quality Score?

Our AI rates COGT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy COGT?

Our AI Timing Score for COGT is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does COGT belong to?

COGENT BIOSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

COGT (NASDAQ) Stock Analysis | COGENT BIOSCIENCES INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

COGT AI Analysis Summary

Our AI summary for COGT: COGENT BIOSCIENCES INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -58.30%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

COGT

COGENT BIOSCIENCES INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 38.93

-2.43 (-5.88%) Day Change

Watchlist Portfolio Compare Chart

0.37

D/E

-58.3%

ROE

-39.2%

ROA

0.00%

Div Yield

COGENT BIOSCIENCES INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 38.93 Price -2.43 (-5.88%) Day Change	NEWS SCORE: 98

COGT, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	38.93
PBV / Sector	11.63 / 5.20
Earning Per Share	-1.95

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	82.48 M
Average 1W Daily Value	57.31 M

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-39.24 / 27.02
ROA Average (%) / Sector	-51.57 / -368.17
ROA Change Average (%) / Sector	5.78 / 5,404.12
ROE (%) / Sector	-58.30 / 3.47
ROE Average (%) / Sector	-67.27 / 6.51
ROE Change Average (%) / Sector	10.56 / 2,128.13 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:39
Symbol	COGT
Name	COGENT BIOSCIENCES INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	170.87 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	7,067.10 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 275 Wyman Street, Waltham, MA, United States, 02451

Phone: 617 945 5576

Website: https://www.cogentbio.com

Employees: 258

Sector: Healthcare >> Biotechnology

Description: Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.